Free Trial

CytoMed Therapeutics (GDTC) Competitors

CytoMed Therapeutics logo
$1.90 +0.01 (+0.53%)
Closing price 07/24/2025 03:49 PM Eastern
Extended Trading
$1.92 +0.03 (+1.32%)
As of 08:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GDTC vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXW

Should you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry.

CytoMed Therapeutics vs. Its Competitors

180 Life Sciences (NASDAQ:ATNFW) and CytoMed Therapeutics (NASDAQ:GDTC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

0.0% of CytoMed Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

180 Life Sciences has higher earnings, but lower revenue than CytoMed Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/AN/AN/AN/A
CytoMed Therapeutics$69.50K299.07-$1.84MN/AN/A

In the previous week, CytoMed Therapeutics had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 2 mentions for CytoMed Therapeutics and 1 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 1.89 beat CytoMed Therapeutics' score of 0.82 indicating that 180 Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
180 Life Sciences Very Positive
CytoMed Therapeutics Positive

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A N/A N/A
CytoMed Therapeutics N/A N/A N/A

CytoMed Therapeutics has a consensus target price of $5.00, indicating a potential upside of 163.16%. Given CytoMed Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytoMed Therapeutics is more favorable than 180 Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CytoMed Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

CytoMed Therapeutics beats 180 Life Sciences on 6 of the 7 factors compared between the two stocks.

Get CytoMed Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GDTC vs. The Competition

MetricCytoMed TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$20.68M$3.05B$5.72B$9.47B
Dividend YieldN/A2.40%4.60%3.99%
P/E RatioN/A20.8627.9419.95
Price / Sales299.07317.05452.94100.82
Price / CashN/A43.2336.5558.97
Price / Book3.118.308.645.90
Net Income-$1.84M-$55.19M$3.24B$258.42M
7 Day Performance-6.86%5.81%3.69%2.11%
1 Month Performance-18.10%17.73%10.33%12.44%
1 Year Performance-3.55%4.67%34.30%19.55%

CytoMed Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GDTC
CytoMed Therapeutics
1.5321 of 5 stars
$1.90
+0.5%
$5.00
+163.2%
-5.5%$20.68M$69.50K0.00N/AUpcoming Earnings
High Trading Volume
ATNFW
180 Life Sciences
N/A$0.01
-6.3%
N/A+11.8%$0.00N/A0.007Positive News
Gap Down
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.00
flat
N/AN/A$0.00N/A0.002
AIMDW
Ainos
N/A$0.14
+16.8%
N/AN/A$0.00$106.21K0.0040Positive News
Gap Up
ALVOW
Alvotech
N/A$1.59
-3.6%
N/A-27.2%$0.00$585.60M0.004Positive News
Gap Up
ARAV
ARAVIVE
N/A$0.04
flat
N/AN/A$0.00$9.14M0.0020High Trading Volume
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.04
+75.5%
N/AN/A$0.00N/A0.0015
BFRIW
Biofrontera
N/A$0.10
-11.4%
N/AN/A$0.00$38.00M0.0070Positive News
Gap Down
BTMDW
biote
N/A$0.01
+20.0%
N/A-97.2%$0.00$199.38M0.00N/A
BCTXW
BriaCell Therapeutics
N/A$0.03
-31.8%
N/A-65.8%$0.00N/A0.008Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:GDTC) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners